TWST
Twist BioscienceDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The cleanest post-print positive is operational: 2Q26 revenue beat internal guidance, both DSPS and NGS grew year over year and sequentially, gross margin stayed above 50%, and management raised full-year revenue guidance while reiterating 4Q26 adjusted EBITDA breakeven [#8-K-2026-05-04].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +0.4.
What can break
Competition is intense across synthetic biology, gene synthesis, and NGS sample-prep markets, including providers such as GenScript, IDT/Danaher, Thermo Fisher, and Illumina; stronger incumbents can pressure pricing, product breadth, and turnaround times [#10-K-2025-11-17].
Momentum
98
Value
41
Sentiment
5
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $54.00 · Bull $66.00 · Bear $45.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $99.56
Why
Momentum98 · Δ7d +0.4
Value41 · Δ7d -0.1
Sentiment5 · Δ7d -3.3
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
98
26% active weight
Current posture
7d trendImproving
Δ7d
+0.4
Δ21d
+0.1
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
5
34% active weight
Current posture
7d trendSoftening
Δ7d
-3.3
Δ21d
+2.0
Why this grade
Composite grade D. Momentum 97.6 / Value 41.1 / Sentiment 4.8
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$5.45B
Beta
2.23
Shares Out
62.27M
P/E (TTM) · Derived
-67.3
P/S (TTM)
5.58
P/FCF (TTM) · Derived
-56.21
Rev YoY
+19.3%
EPS YoY
+8.2%
Gross Margin
+52.1%
Op Margin
-36.2%
Net Debt
-$156.86M
Current Ratio
2.70
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology

